Skip to content

Acs: 180 and Advia Centaur Anti-Thyroglobulin Immunoassays

by Bayer Corp.

510(k) K012777

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None ongoing

4 closed

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 11 Oct 2026. What this means

Regulatory status

as of registry sync 11 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK012777 Date22 Oct 2001ClearedStatusActive

Recalls

4 recalls · FDA

  • 4 recalls, same reason

    • Terminated Z-1236-2019 FDA Class II initiated 7 Dec 2018
    • Terminated Z-1235-2019 FDA Class II initiated 7 Dec 2018
    • Terminated Z-1233-2019 FDA Class II initiated 7 Dec 2018
    • Terminated Z-1234-2019 FDA Class II initiated 7 Dec 2018

    Positive bias anti-thyroglobulin with ADVIA Centaur aTG kit lots ending in 316 and lower and Atellica IM aTG kit lots ending in 317 and lower when compared to the standardization to World Health Organization (WHO) Reference Preparation MRC 65/93 stated in the Instructions for Use (IFU).

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
JZO
Device Class
Class II
Regulation
21 CFR Part 866.5870
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Other devices from Bayer Corp.

See all devices from Bayer Corp. →